Prevalence, predictors, and outcomes of clonal hematopoiesis in individuals aged ≥80 years
Open accessThe DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.
Abstract
Clonal hematopoiesis (CH), characterized by a fraction of peripheral blood cells carrying an acquired genetic variant, emerges with age. Although in general CH is associated with increased mortality and morbidity, no higher risk of death was observed for individuals ≥80 years. Here, we investigated CH in 621 individuals aged ≥80 years from the population-based LifeLines cohort. Sensitive error-corrected sequencing of 27 driver genes at a variant allele frequency ≥1% revealed CH in the majority (62%) of individuals, independent of gender. The observed mutational spectrum was dominated by DNMT3A and TET2 variants, which frequently (29%) displayed multiple mutations per gene. In line with previous results in individuals ≥80 years, the overall presence of CH did not associate with a higher risk of death (hazard ratio, 0.91; 95% confidence interval, 0.70-1.18; P = .48). Being able to assess the causes of death, we observed no difference between individuals with or without CH, except for deaths related to hematological malignancies. Interestingly, comparison of mutational spectra confined to DNMT3A and TET2 vs spectra containing other mutated genes, showed a higher risk of death when mutations other than DNMT3A or TET2 were present (hazard ratio, 1.48; 95% confidence interval, 1.06-2.08; P = .025). Surprisingly, no association of CH with cardiovascular morbidity was found, irrespective of clone size. Further, CH associated with chronic obstructive pulmonary disease. Data on estimated exposure to DNA damaging toxicities (ie, smoking, a history of cancer [as a proxy for previous genotoxic therapy], and job-related pesticide exposure) showed an association with spliceosome and ASXL1 variants, but not with DNMT3A and TET2 variants.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Age-related clonal hematopoiesis associated with adverse outcomes
Jaiswal, S., Fontanillas, P., Flannick, J., Manning, A., Grauman, P. V., Mar, B. G., Lindsley, R. C., Mermel, C. H., Burtt, N., Chavez, A., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1408617 · Cited by 4,841
Clonal hematopoiesis and blood-cancer risk inferred from blood DNA sequence
Genovese, G., Kähler, A. K., Handsaker, R. E., Lindberg, J., Rose, S. A., Bakhoum, S. F., Chambert, K., Mick, E., Neale, B. M., Fromer, M., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1409405 · Cited by 3,531 · cited 2×
“Whole-exome sequencing has revealed CH to be virtually absent in individuals younger than 30 years of age, while being present in 20% to 30% of individuals aged 50 to 60 years.(1,2) By using a more sensitive sequencing technique, small clones were shown to be almost”
BackgroundMethodClonal hematopoiesis and risk of atherosclerotic cardiovascular disease
Jaiswal, S., Natarajan, P., Silver, A. J., Gibson, C. J., Bick, A. G., Shvartz, E., McConkey, M., Gupta, N., Gabriel, S., Ardissino, D., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1701719 · Cited by 2,683
Coombs, C. C., Zehir, A., Devlin, S. M., Kishtagari, A., Syed, A., Jonsson, P., Hyman, D. M., Solit, D. B., Robson, M. E., Baselga, J., et al. (2017) · Cell stem cell · doi:10.1016/j.stem.2017.07.010 · Cited by 866
Clonal hematopoiesis, with and without candidate driver mutations, is common in the elderly
Zink, F., Stacey, S. N., Norddahl, G. L., Frigge, M. L., Magnusson, O. T., Jonsdottir, I., Thorgeirsson, T. E., Sigurdsson, A., Gudjonsson, S. A., Gudmundsson, J., et al. (2017) · Blood · doi:10.1182/blood-2017-02-769869 · Cited by 777
Clonal haematopoiesis harbouring AML-associated mutations is ubiquitous in healthy adults
Young, A. L., Challen, G. A., Birmann, B. M., & Druley, T. E. (2016) · Nature Communications · doi:10.1038/ncomms12484 · Cited by 692
Somatic mutations precede acute myeloid leukemia years before diagnosis
Desai, P., Mencia-Trinchant, N., Savenkov, O., Simon, M. S., Cheang, G., Lee, S., Samuel, M., Ritchie, E. K., Guzman, M. L., Ballman, K. V., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0081-z · Cited by 619
Stolk, R. P., Rosmalen, J. G. M., Postma, D. S., de Boer, R. A., Navis, G., Slaets, J. P. J., Ormel, J., & Wolffenbuttel, B. H. R. (2008) · European Journal of Epidemiology · doi:10.1007/s10654-007-9204-4 · Cited by 391 · cited 1×
“A broad range of investigative procedures are performed at multiple time points with the aim of assessing the biomedical, sociodemographic, behavioral, physical, and psychological factors contributing to health and disease of the general population, with a special focus on multimorbidity and complex genetics.(19) The…”
BackgroundClonal haematopoiesis: connecting ageing and inflammation in cardiovascular disease
Jaiswal, S., & Libby, P. (2020) · Nature Reviews Cardiology · doi:10.1038/s41569-019-0247-5 · Cited by 386
Buscarlet, M., Provost, S., Zada, Y. F., Barhdadi, A., Bourgoin, V., Lépine, G., Mollica, L., Szuber, N., Dubé, M.-P., & Busque, L. (2017) · Blood · doi:10.1182/blood-2017-04-777029 · Cited by 383 · cited 1×
“hypothesis, the high prevalence of DT clones in this elderly cohort may indicate a (beneficial) mechanism by which these clones compensate for a functional decline of aging stem cells to maintain normal hematological output.(27,28) Indeed, when comparing the survival impact of mutational spectra confined to TET2 and D…”
Background
Cited by
Association of clonal hematopoiesis with chronic obstructive pulmonary disease
Miller, P. G., Qiao, D., Rojas-Quintero, J., Honigberg, M. C., Sperling, A. S., Gibson, C. J., Bick, A. G., Niroula, A., McConkey, M. E., Sandoval, B., et al. (2022) · Blood · doi:10.1182/blood.2021013531 · Cited by 235
“13-16 In this study, we sought to de fi nitively assess the association between CHIP and COPD through analyses of whole-genome sequencing and whole-exome sequencing data from several large, extensively pheno-typed cohorts of COPD patients and controls.”
Causes and consequences of clonal hematopoiesis
Weeks, L. D., & Ebert, B. L. (2023) · Blood · doi:10.1182/blood.2023022222 · Cited by 169
Clonal hematopoiesis: Mutation-specific adaptation to environmental change
Florez, M. A., Tran, B. T., Wathan, T. K., DeGregori, J., Pietras, E. M., & King, K. Y. (2022) · Cell Stem Cell · doi:10.1016/j.stem.2022.05.006 · Cited by 129
Evolutionary landscape of clonal hematopoiesis in 3,359 individuals from the general population
van Zeventer, I. A., de Graaf, A. O., Salzbrunn, J. B., Nolte, I. M., Kamphuis, P., Dinmohamed, A., van der Reijden, B. A., Schuringa, J. J., Jansen, J. H., & Huls, G. (2023) · Cancer Cell · doi:10.1016/j.ccell.2023.04.006 · Cited by 91
Self-citation
Metadata
- Authors
- van Zeventer, I. A., Salzbrunn, J. B., de Graaf, A. O., van der Reijden, B. A., Boezen, H. M., Vonk, J. M., van der Harst, P., Schuringa, J. J., Jansen, J. H., & Huls, G.
- Venue
- Blood Advances
- Publisher
- American Society of Hematology
- Published
- 2021-04-20
- Volume
- 5
- Issue
- 8
- Pages
- 2115-2122
- ISSN
- 2473-9529 (ISSN-L)
- 2473-9537
- OpenAlex
- W3155628987
- Cited by
- 83
- References
- 13
- FWCI
- 7.49
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Prevalence, predictors, and outcomes of clonal hematopoiesis in individuals aged ≥80 years. https://app.cochat.ai/papers/10.1182/bloodadvances.2020004062
- The paper
- van Zeventer, I. A., Salzbrunn, J. B., de Graaf, A. O., van der Reijden, B. A., Boezen, H. M., Vonk, J. M., van der Harst, P., Schuringa, J. J., Jansen, J. H., & Huls, G. (2021). Prevalence, predictors, and outcomes of clonal hematopoiesis in individuals aged ≥80 years. Blood Advances. https://doi.org/10.1182/bloodadvances.2020004062
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.